Personalized 3D Vaccine Integrates Immunotherapy and Antiangiogenic Therapy to Prevent Oral Squamous Cell Carcinoma Recurrence

The immune-suppressive microenvironment and extensive tumor angiogenesis are key contributors to the high recurrence and mortality rates of oral squamous cell carcinoma (OSCC). To address these challenges, a personalized 3D-printed anti-tumor vaccine (3D-Vax-L) is developed that integrates whole tumor antigens from postoperative tissue lysates with the angiogenesis inhibitor, lenvatinib. This vaccine not only possesses inherent adjuvant properties but also mimics the functions of lymph nodes through its porous structure, facilitating the recruitment and maturation of immune cells. In vivo studies in OSCC animal models, including mice and rabbits, demonstrate that 3D-Vax-L effectively recruits and matures immune cells at postoperative sites, inhibits angiogenesis and tumor recurrence, and extends survival time, all while maintaining a stable morphology and an excellent biosafety. Furthermore, 3D-Vax-L supports facial integrity post-surgery, addressing physical challenges by preventing collapse and reducing the risk of aesthetic-related disorders. These findings suggest that 3D-Vax-L is a promising therapeutic technique for preventing post-surgical OSCC relapse, particularly as it offers a new strategy for immune system activation and demonstrates significant potential for clinical translation.

Authors

Institutions

Publication Details

Journal
Advanced Materials
Published
2025-07-24
DOI
https://doi.org/10.1002/adma.202417708
Citations
3
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
2.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Personalized 3D Vaccine Integrates Immunotherapy and Antiangiogenic Therapy to Prevent Oral Squamous Cell Carcinoma Recurrence

Gengtian Sun, M.-F. Li, Yuguang Wang, Bozhao Li et al.
3 citations
Advanced Materials
Immunotherapy and Immune Responses
2.39
article

Personalized 3D Vaccine Integrates Immunotherapy and Antiangiogenic Therapy to Prevent Oral Squamous Cell Carcinoma Recurrence

Gengtian Sun, M.-F. Li, Yuguang Wang, Bozhao Li, Peng Yue, Guangjun Nie, Suying Wu, Tianjiao Chu, Fei Wu, Zefang Lu, Feilong Qi, Suping Li, Yuliang Zhao, Zhenlin Yang, Jinna Ren
article en
3 citations

Abstract

The immune-suppressive microenvironment and extensive tumor angiogenesis are key contributors to the high recurrence and mortality rates of oral squamous cell carcinoma (OSCC). To address these challenges, a personalized 3D-printed anti-tumor vaccine (3D-Vax-L) is developed that integrates whole tumor antigens from postoperative tissue lysates with the angiogenesis inhibitor, lenvatinib. This vaccine not only possesses inherent adjuvant properties but also mimics the functions of lymph nodes through its porous structure, facilitating the recruitment and maturation of immune cells. In vivo studies in OSCC animal models, including mice and rabbits, demonstrate that 3D-Vax-L effectively recruits and matures immune cells at postoperative sites, inhibits angiogenesis and tumor recurrence, and extends survival time, all while maintaining a stable morphology and an excellent biosafety. Furthermore, 3D-Vax-L supports facial integrity post-surgery, addressing physical challenges by preventing collapse and reducing the risk of aesthetic-related disorders. These findings suggest that 3D-Vax-L is a promising therapeutic technique for preventing post-surgical OSCC relapse, particularly as it offers a new strategy for immune system activation and demonstrates significant potential for clinical translation.

Advanced MaterialsVol. 37(39)
Jinan University (CN), Jilin University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Harbin Institute of Technology (CN), Inner Mongolia University (CN), Beijing Chao-Yang Hospital, Capital Medical University (CN), Chinese PLA General Hospital (CN), National Clinical Research (US), Stomatology Hospital (CN), National Center for Nanoscience and Technology (CN), University of Chinese Academy of Sciences (CN)
National Natural Science Foundation of China, National Key Research and Development Program of China
Openalex Percentile: Top 10%
Immunotherapy and Immune Responses
2.39
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.